期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 184, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejps.2023.106415
关键词
Hyponatremia; Syndrome of inappropriate antidiuretic; hormone secretion; SGLT-2 inhibitors; Osmotic diuresis
Hyponatremia is a common electrolyte disorder that can have life-threatening complications. It is associated with increased hospital stays, costs, morbidity, and mortality. Recent studies have shown that oral administration of SGLT 2i is an effective treatment for hyponatremia.
Hyponatremia is the most common electrolyte disorder in clinical practice, which may lead to life-threatening complications. Several lines of evidence suggest that hyponatremia is associated not only with significant in-creases in length of stay, cost, and financial burden, but also with increased morbidity and mortality. Hypona-tremia is also considered to be a negative prognostic factor in patients with heart failure and cancer. Although multiple therapeutic methods are available for treating hyponatremia, most have some limitations, such as poor compliance, rapid correction of serum Na+, other negative side effects and high cost. Given these limitations, identifying novel therapies for hyponatremia is essential. Recent clinical studies have shown that SGLT-2 in-hibitors (SGLT 2i) significantly increased serum Na+ levels and were well tolerated by patients who underwent this treatment. Therefore, oral administration of SGLT 2i appears to be an effective treatment for hyponatremia. This article will briefly review the etiology of hyponatremia and integrated control of sodium within the kidney, current therapies for hyponatremia, potential mechanisms and efficacy of SGLT 2i for hyponatremia, and the benefits in cardiovascular, cancer, and kidney disease by regulating sodium and water balance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据